Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management
Abstract Hypertension is one of the most common comorbidity and the leading cause of cancer-related death in cancer patients. The prevalence of hypertension in cancer patients is much higher than that of the general population. In the older population of cancer patients, specific cancer treatments s...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40959-023-00197-8 |
| _version_ | 1797388103174848512 |
|---|---|
| author | Amir Askarinejad Azin Alizadehasl Amir Ghaffari Jolfayi Sara Adimi |
| author_facet | Amir Askarinejad Azin Alizadehasl Amir Ghaffari Jolfayi Sara Adimi |
| author_sort | Amir Askarinejad |
| collection | DOAJ |
| description | Abstract Hypertension is one of the most common comorbidity and the leading cause of cancer-related death in cancer patients. The prevalence of hypertension in cancer patients is much higher than that of the general population. In the older population of cancer patients, specific cancer treatments such as new tyrosine kinase inhibitors and Vascular endothelial growth factor inhibitor drugs give rise to hypertension in cancer patients; The aim of present study is to provide a detailed discussion etiologies of cancer treatment-induced hypertension and explore the most innovative diagnostic and management approaches. This review will address the optimal approach to hypertension treatment, covering treatment initiation thresholds, targets, and the selection of anti-hypertensive agents. The lack of evidence in recent guidelines for managing cardiovascular toxicities in cancer patients can create uncertainty in clinicians' therapeutic and clinical decisions. This review aims to enhance our understanding of hypertension etiology in cancer patients and provide a practical guide to current treatment approaches. |
| first_indexed | 2024-03-08T22:34:55Z |
| format | Article |
| id | doaj.art-fdd4762f45f345aaa5d444d1c3a1632e |
| institution | Directory Open Access Journal |
| issn | 2057-3804 |
| language | English |
| last_indexed | 2024-03-08T22:34:55Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardio-Oncology |
| spelling | doaj.art-fdd4762f45f345aaa5d444d1c3a1632e2023-12-17T12:31:28ZengBMCCardio-Oncology2057-38042023-12-019111310.1186/s40959-023-00197-8Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and managementAmir Askarinejad0Azin Alizadehasl1Amir Ghaffari Jolfayi2Sara Adimi3Rajaie Cardiovascular Medical and Research Center, Iran University of Medical SciencesCardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical SciencesRajaie Cardiovascular Medical and Research Center, Iran University of Medical SciencesCardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical SciencesAbstract Hypertension is one of the most common comorbidity and the leading cause of cancer-related death in cancer patients. The prevalence of hypertension in cancer patients is much higher than that of the general population. In the older population of cancer patients, specific cancer treatments such as new tyrosine kinase inhibitors and Vascular endothelial growth factor inhibitor drugs give rise to hypertension in cancer patients; The aim of present study is to provide a detailed discussion etiologies of cancer treatment-induced hypertension and explore the most innovative diagnostic and management approaches. This review will address the optimal approach to hypertension treatment, covering treatment initiation thresholds, targets, and the selection of anti-hypertensive agents. The lack of evidence in recent guidelines for managing cardiovascular toxicities in cancer patients can create uncertainty in clinicians' therapeutic and clinical decisions. This review aims to enhance our understanding of hypertension etiology in cancer patients and provide a practical guide to current treatment approaches.https://doi.org/10.1186/s40959-023-00197-8Cardio-oncologyHypertensionVascular endothelial growth factor inhibitorTyrosine kinase inhibitors |
| spellingShingle | Amir Askarinejad Azin Alizadehasl Amir Ghaffari Jolfayi Sara Adimi Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management Cardio-Oncology Cardio-oncology Hypertension Vascular endothelial growth factor inhibitor Tyrosine kinase inhibitors |
| title | Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management |
| title_full | Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management |
| title_fullStr | Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management |
| title_full_unstemmed | Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management |
| title_short | Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management |
| title_sort | hypertension in cardio oncology clinic an update on etiology assessment and management |
| topic | Cardio-oncology Hypertension Vascular endothelial growth factor inhibitor Tyrosine kinase inhibitors |
| url | https://doi.org/10.1186/s40959-023-00197-8 |
| work_keys_str_mv | AT amiraskarinejad hypertensionincardiooncologyclinicanupdateonetiologyassessmentandmanagement AT azinalizadehasl hypertensionincardiooncologyclinicanupdateonetiologyassessmentandmanagement AT amirghaffarijolfayi hypertensionincardiooncologyclinicanupdateonetiologyassessmentandmanagement AT saraadimi hypertensionincardiooncologyclinicanupdateonetiologyassessmentandmanagement |